In the other report, Celgene Inc. 's Revlimid doubled the number of myeloma patients whose disease remained in remission three years after treatment began, compared with those on placebo.
在另外一篇报告里，Celgene公司的Revlimid药在开始服用后的三年内脊髓瘤患者处于缓解期的人数比服用安慰剂组的数量增加了一倍。
Revlimid, which is approved for multiple myeloma patients in combination with the steroid dexamethasone, and for a rare condition called myelodysplastic syndromes, had revenue of $1.7 billion in 2009.
Revlimid和类固醇地塞米松联合用药被批准用于多发性脊髓瘤和罕见病骨髓增生异常综合征 的治疗。 其2009年的销售额为17亿美元。
Revlimid, which is approved for multiple myeloma patients in combination with the steroid dexamethasone, and for a rare condition called myelodysplastic syndromes, had revenue of $1.7 billion in 2009.
Revlimid和类固醇地塞米松联合用药被批准用于多发性脊髓瘤和罕见病骨髓增生异常综合征 的治疗。 其2009年的销售额为17亿美元。
应用推荐